Dermal cytochrome P450 1A inhibitors and enhancers

摘要: The present invention provides dermal cytochrome P450 1A (CYP1A) inhibitors, which include free base or pharmacologically acceptable salt of (−)-epicatechin, (+)-epicatechin, (+)-limonene, 3-phenylpropyl acetate, α-naphthoflavone, apigenin, baicalein, baicalin, β-myrcene, catechin, β-naphthoflavone, cineole, daidzein, daidzin, diosmin, ergosterol, formononetin, gallic acid, genistein, glycyrrhizin, glycyrrhizic hesperetin, hesperidin, isoquercitrin, kaempferol, lauryl alcohol, luteolin, luteolin-7-glycoside, narigenin, narigin, nordihydroguaiaretic oleanolic paeoniflorin, quercetin, quercitrin, rutin, swertiamarin, terpineol, trans-cinnamaldehyde, trans-cinnamic umbelliferone, genkwanin, homoorientin, isovitexin, neohesperidin, wongonin, capillarisin, liquiritin, ethyl myristate, poncirin, and ursolic acid. CYP1A inhibitors can be co-administered with compounds first-pass effect such as dermatological drugs to improve the bioavailability drugs. also enhancers, (+)-catechin, protocatechuic umbellic